LUGPA Bladder Cancer Highlights: Key Trials and Trends for 2025

Sia Daneshmand, MD, of Keck Medicine of USC, talks about the biggest developments and key highlights in bladder cancer from the LUGPA 2024 Annual Meeting, including the recent approval of ANKTIVA and the SunRISe-1 study of the TAR-200 drug delivery system for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 will take place September 27-29 in Nashville, Tennessee.

This meeting is the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Gordon Brown, DOUrothelial Carcinoma | November 25, 2024
Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.
View More
Gautam Jayram, MDRenal Cell Carcinoma | November 25, 2024
Dr. Jayram breaks down important topics in kidney cancer from LUGPA 2024, including adjuvant pembrolizumab post-nephrectomy.
Gautam Jayram, MDUrothelial Carcinoma | November 25, 2024
Dr. Jayram provides insights into the BCG-unresponsive and BCG-naive bladder cancer space at the LUGPA 2024 Annual Meeting.
Jason Hafron, MDUpper Tract Urothelial Carcinoma | November 22, 2024
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.

Video Insights

Clinical discussions with experts in the field

Network Websites